REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Enzyme Or Coenzyme Containing > Hydrolases (3. ) (e.g., Urease, Lipase, Asparaginase, Muramidase, Etc.) Hydrolases (3. ) (e.g., Urease, Lipase, Asparaginase, Muramidase, Etc.)Hydrolases (3. ) (e.g., Urease, Lipase, Asparaginase, Muramidase, Etc.) patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.08/09/07 - 20070184046 - Use of a phospholipase a2 for the preparation of pharmaceutical and/or cosmetic compositions for the local and/or systematic treatment and/or prevention of diseases and/or processes caused by intra- and extracellular pathogens expressing membrane phosphol The invention relates to the use of phospholipases, v.gr. sPLA2, as an active agent in the production of pharmaceutical and/or cosmetic compositions for the treatment of diseases caused by micro-organisms, the envelope or membrane of which comprises phospholipids, particularly glycerophospholipids. In particular, said invention relates to the use of sPLA2 ... 08/09/07 - 20070184045 - Large-scale production of human serum butyrylcholinesterase as a bioscavenger Disclosed herein are methods for the large-scale preparation of human butyrylcholinesterase (HuBChE) preparations from Cohn Fraction IV-4. As disclosed, the methods provide HuBChE preparations that are about 99% or more pure with recovery yields of about 60%. Also disclosed are the pharmacokinetics, safety and toxicity, stability and efficacy of the ... 07/26/07 - 20070172470 - Phosphatase regulation of nucleic acid transcription Nucleic acids, polypeptides and methods are provided for regulating the phosphorylation state of the C-terminal domain (CTD) of RNA polymerase II (RNAP II). Also provided are methods for regulating cell differentiation. ... 07/12/07 - 20070160592 - Method for treatment of macular degeneration The present invention provides a method for treating macular degeneration utilizing a therapeutic agent delivery system that is disposed in proximity of the sclera after which one or more therapeutic agents are injected or diffused into the sclera to provide for the dissolution of waste products in Bruch's membrane. ... 07/05/07 - 20070154467 - Detection of mutations in a gene associated with resistance to viral infection, oas1 A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the ... 06/07/07 - 20070128179 - Phospholipase(s) and use(s) thereof The present invention provides a method for the treatment and/or prevention of a bacterial related condition comprising administering to a subject a therapeutically effective amount of at least one phospholipase, isoform, derivative, mutant and/or fragment thereof. The phospholipase, isoform, derivative, mutant and/or fragment thereof, may be obtained from at least ... 05/10/07 - 20070104702 - Method for treating diseases associated with changes of qualitative and/quantitative composition of blood extracellular dna The invention relates to medicine and veterinary science and can be used for treating diseases associated with changes of the qualitative and/quantitative composition of blood extracellular DNA, namely generalised infection diseases provoked by bacteria, diseases provoked by fungi and protozoa, atherosclerosis, pancreatic diabetes, allergic diseases associated with delayed response hypersensitivity ... 04/26/07 - 20070092503 - Human alkaline sphingomyelinase and use thereof An isolated human alkaline sphingomyelinase (Alk-Smase) or a variant thereof is capable of hydrolysing sphingomyelin. Methods are provided for isolating human Alk-Smase and for preparing human recombinant Alk-Smase. Further methods are provided for the use of the enzyme for the treatment of colon cancer. ... 04/12/07 - 20070081984 - Compositions and methods for treating hypophosphatasia The present invention provides compositions and methods for use in enzyme replacement therapy. The inventors disclose a method of producing membrane bound enzymes in an active soluble form by eliminating the glycosylphosphatidylinositol (GPI) membrane anchor. In particular the inventors disclose a soluble active form of the membrane bound enzyme TNSALP ... 03/15/07 - 20070059300 - Compounds and compositions to control abnormal cell growth Methods and regimens for stimulating proliferation and inhibiting death of skin cells in wounded, non-wounded healthy and unhealthy, or transplanted skin and skin cell suspensions are provided. The methods and regimens include a step of administering to an area of host skin and/or transplanted skin a combination of lactoferrin and ... 03/08/07 - 20070053897 - Calcium independent cytosolic phospholipase a2/b enzymes The invention provides a novel calcium-independent cytosolic phospholipase A2/B enzyme, polynucleotides encoding such enzyme and methods for screening unknown compounds for anti-inflammatory activity mediated by the arachidonic acid cascade. ... 02/01/07 - 20070025977 - Method of treating steatorrhea in infants A method for treating steatorrhea in infants in need thereof by administering to the infant an amount of pancrelipase of from about 300 to about 2,500 USP units lipase/kg/meal or from about 1,500 to about 7,500 USP units lipase/kg/day. ... 01/18/07 - 20070014778 - Endoribonuclease and uses thereof The invention provides in part a substantially pure endoribonuclease, having a molecular weight of about 34-48 KDa on a 12% denaturing sodium dodecyl sulfate polyacrylamide gel and capable of preferentially cleaving a RNA molecule at sites 3′ of uracil residues or sites 5′ of adenine residues. The invention provides methods ... 01/18/07 - 20070014777 - Protein compositions for promoting wound healing and skin regeneration Methods for stimulating proliferation and inhibiting death of cells in the epidermis and dermis of wounded and non-wounded as well as transplanted mammalian skin and transplanted skin cell suspensions are described. The methods include the steps of administering to an area of wounded or non-wounded skin therapeutically effective amounts of ... 01/04/07 - 20070003537 - Cytotoxic ribonuclease variants This invention relates to altered forms of members of the RNase A superfamily. An RNase A can be modified to be cytotoxic by altering its amino acid sequence so that it is not bound easily by the ribonuclease inhibitor while still retaining catalytic properties. While earlier work had identified some ... 12/28/06 - 20060292137 - Cytotoxic ribonuclease variants This invention relates to cytotoxic variants of human ribonuclease 1 (RNase 1) identified through analysis of the interaction between RNase 1 and the human ribonuclease inhibitor (hRI) as defined by the three dimensional (3-D) atomic structure of the RNase 1 hRI complex. Also disclosed is the 3-D structure of the ... 12/21/06 - 20060286085 - Tissue inhibitor of metalloproteinase type three (timp-3) composition and methods The present invention relates in general to metalloproteinase inhibitors and to polynucleotides encoding such inhibitors. In particular, the invention relates to novel mammalian inhibitors of metalloproteinase, which are designated as type three or TIMP-3, to fragments, derivatives, and analogs thereof, and to polynucleotides encoding the same. Novel methods of producing ... 12/14/06 - 20060280730 - Induction of apoptosis of malignant cells by activation of calcium-activated potassium channels Disclosed are a method of inducing apoptosis of a malignant cell, which employs a calcium-activated potassium channel (KCa) activator and is useful for treating a malignant tumor in a human subject. Also disclosed are methods of selectively inhibiting the proliferation of malignant cells compared to non-malignant cells in a mixed ... 11/30/06 - 20060269537 - Glycosyl phosphatidyl inositol specific phospholipase d proteins and uses thereof Glycosylphosphatidylinositol specific phospholipase D (GPI-PLD) proteins and their medical uses are disclosed, in particular in the treatment and diagnosis of diabetes and complications of diabetes such as insulin resistance, liver dysfunction, disorders involving pancreatectomies and conditions mediated by a product of an infectious organism which is capable of inhibiting GPI-PLD, ... 11/23/06 - 20060263345 - Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use The invention provides a butyrylcholinesterase variant having increased cocaine hydrolysis activity as well as the corresponding encoding nucleic acid. The invention further provides methods of hydrolyzing a cocaine-based butyrylcholinesterase substrate as well as methods of treating a cocaine-induced condition with the invention variant. ... 11/16/06 - 20060257386 - Cosmetic composition and methods A cosmetic composition is provided having ingredients that may prevent signs of aging, improve the aesthetic appearance of skin, and promote recovery from environmental stresses. The composition includes natural ingredients, including at least one ingredient or extract from rosemary; at least one ingredient or extract from Centella, Echinacea, Alpinia or ... 10/26/06 - 20060239991 - Novel trna synthetase The invention provides tRNA synthetase polypeptides and DNA (RNA) encoding tRNA synthetase polypetides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing tRNA synthetase polypeptide for the protection against infection, particularly bacterial infections. ... 10/19/06 - 20060233780 - Method for treating oncological diseases The invention relates to medicine and veterinary science and can be used for treating mainly solid tumors. The inventive method for treating oncological diseases consisting in injecting a blood extracellular DNA destroying agent into a systemic blood circulation. Said blood extracellular DNA destroying agent can be embodied in the form ... 10/12/06 - 20060228347 - Antitumor agent and dnase An antitumor agent comprising as an active ingredient a DNase, and novel DNases are disclosed. The novel DNases are derived from human stomach cancer cell line MKN-28 or human cervical cancer cell line HeLa, and do not act on normal cells but specifically act on cancer cells. ... 08/17/06 - 20060182733 - Atp diphosphohydrolase (cd39) gene therapy for inflammatory or thrombotic conditions and transplantation and means there for A method to render endothelial cells capable of inhibiting platelet and leukocyte-mediated injury and inflammation is described, comprising genetically modifying the cells by inserting DNA encoding ecto-ATP diphosphohydrolase or an oxidation-resistant analog thereof, and expressing a protein having functional ecto-ATP diphosphohydrolase activity, such as the human CD39 protein, by said ... 08/03/06 - 20060171938 - Compositions and methods for enhancing cognitive function The invention encompasses novel compositions containing a methylation modifying compound isolated from botanical raw materials, including a fruit of the genus Coffea, and microbial raw materials, methods of making such compositions, and methods of treating or preventing human disease using such compositions. The methylation modifying compound in botanical extracts of ... 07/13/06 - 20060153825 - Use of protein histidine phosphatase The invention relates to the use of polypeptides with protein histidine phosphatase activity derived from mammalians, antibodies directed against them and DNA or RNA sequences complementary to mRNA sequences encoding polypeptides with protein histidine phosphatase activity for the modulation of ATP-citrate lyase and treatment of correlated pathophysiologic functions. ... 07/06/06 - 20060147441 - Plasminogen fragment having activity to inhibit tumor metastasis and growth and process for preparing same technical field The present invention provides a plasminogen fragment with the activity to inhibit tumor metastasis and growth, a process for preparing said fragment and an agent for inhibiting tumor metastasis and growth comprising said fragment as an active ingredient. The plasminogen fragment of the present invention is prepared from a elastase ... 06/22/06 - 20060134090 - Method and dietary composition for improving lipid digestibility A method of providing a pet with a benefit relating to effective assimilation of a lipid is described wherein the pet is administered, as a part of, or in addition to its regular diet, an edible composition that contains an ingredient that maintains, promotes or enhances the capacity of the ... 05/18/06 - 20060104967 - Method of converting the state of proteins Since the mechanism of conversion of the state of actin and myosin or the filaments containing myosin from the relaxed to the catch had not been totally clear and its reconstitution was not easily carried out, a method of converting the state of the muscle proteins from the relaxed state, ... 05/11/06 - 20060099200 - Pretreatment or post exposure treatment for exposure to a toxic substance by pulmonary delivery (inhaler) of a bioscavenger The present invention relates to a treatment by pulmonary delivery of bioscavengers to animals as an effective antidote to prevent toxicity produced by exposure of an animal to nerve agents and other toxic substances. ... 04/13/06 - 20060078553 - Diverse multi-unit complexes including a trna synthetase fragment The present invention relates to compositions comprising a Met-tRNA synthetase fragment and a non-Met-tRNA synthetase fragment as well as uses thereof. In some embodiments, the Met-tRNA synthetase fragment is more than 50% of the composition. In other embodiments, the non-Met-tRNA synthetase fragment is more than 50% of the composition. Such ... 04/13/06 - 20060078552 - Hybrid and single chain meganucleases and use thereof This patent application relates to hybrid and/or single-chain rare-cutting endonucleases, called meganucleases, which recognized and cleave a specific nucleotide sequence, to polynucleotide sequences encoding for said rare-cutting endonucleases, to a vector comprising one of said polynucleotide sequences, to a cell or animal non-human comprising one of said polynucleotide sequences or ... 03/09/06 - 20060051339 - Composition for treatment of oily skin and acne prevention and methods of making and using same Compositions and methods for the prevention and treatment of oily skin and the prevention and treatment of open comedos and acne using the enzyme lipase and an acceptable carrier are disclosed. ... 02/16/06 - 20060034819 - Proteins and methods useful for assessing risk of cardiovascular disease The invention relates to a mutant protein comprising at least a fragment of a mutant dimethylarginine dimethylaminohydrolase (DDAH) enzyme, wherein the fragment possesses an affinity for asymmetric N,N-dimethyl arginine (ADMA) and/or L,N-monomethylarginine (LNMMA), which exists at lower plasma levels than ADMA, and is deficient in hydrolyzing ADMA or LNMMA to ... 02/16/06 - 20060034818 - Placental alkaline phosphatase to control diabetes The present invention provides methods for using human placental alkaline phosphatase or an active derivative to reduce blood glucose level in a mammal. Treatment regimens provided by the invention may be used to control Type 1 and Type 2 forms of diabetes in humans. The methods and treatment regimens may ... 01/12/06 - 20060008455 - Methods and compositions for using aleveolar macrophage phospholipase a2 The present invention is directed to methods and compositions for improving pulmonary surfactant catabolism. More specifically, the specification describes methods and compositions for making and using a lysosomal phospholipase A2 in methods for the diagnosis, and treatment of disorders of phospholipid catabolism such as pulmonary alveolar proteinosis. ... 01/12/06 - 20060008454 - Use of a compound for enhancing the expression of membrane proteins on the cell surface The present invention is directed to the use of a compound stimulating deubiquitinating activity in a cell for the manufacture of a medicament for enhancing the expression of integral membrane proteins on the cell surface. Especially, the invention is directed to the use of such compound for the manufacture of ... 12/29/05 - 20050287133 - Precursor n-acetylgalactosamine-4 sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme The present invention provides a highly purified recombinant, human precursor N-acetylgalactosamine-4-sulfatase and biologically active mutants, fragments and analogs thereof as well as pharmaceutical formulations comprising highly purified recombinant human precursor N-acetylgalactosamine-4-sulfatase. The invention also provides methods for treating diseases caused all or in part by deficiencies in human N-acetylgalactosamine-4-sulfatase including ... 12/22/05 - 20050281803 - Methods and compositions for using aleveolar macrophage phospholipase a2 The present invention is directed to methods and compositions for improving pulmonary surfactant catabolism. More specifically, the specification describes methods and compositions for making and using a lysosomal phospholipase A2 in methods for the diagnosis, and treatment of disorders of phospholipid catabolism such as pulmonary alveolar proteinosis. ... 12/15/05 - 20050276796 - Proteins with an attached short peptide of acidic amino acids Disclosed are a fusion protein comprising enzyme N-acetylgalactosamine-6-sulfate sulfatase and a short peptide consisting of 4-15 acidic amino acids attached to the enzyme on its N-terminal side, a pharmaceutical composition containing the fusion protein, and a method for treatment of type A Morquio disease using the fusion protein. Compared with ... 12/01/05 - 20050265986 - Sphingomyelinase compositions and use thereof The use of sphingomyelinase to increase the levels of skin and mucosal ceramides, as well as dermatological and cosmetic compositions containing same which are suitable for topical application are disclosed. ... 11/24/05 - 20050260184 - Dual roles of pepper esterase as a biocontrol agent This invention relates to dual roles of the pepper esterase protein as a biocontrol agent that can elicit defense reactions in plant cells and as direct fungal inhibitor that can block fungal penetration into plant cells. The possible enzymatic actions of the PepEST protein were elucidated in both fungus and ... 11/24/05 - 20050260183 - Treatment of surfaces populated by bacteria with a lucilia sericata extract A surface populated by a bacteria capable of producing a biofilm is treated beneficially by contacting it with a substance having N-acyl homoserine lactone degradant activity obtained from the secretions and/or excretions of the larval form of the green bottle fly, Lucilia sericata. Furthermore, a synergistic effect is achieved when ... 11/10/05 - 20050249716 - Galenic formulation for colon targeted delivery of active principles Forms of colonic delivery suited to be used orally and designed for colonic delivery of active ingredients selected from the group comprising enzymes capable of inactivating macrolide antibiotics and related compounds, enzymes capable of inactivating quinolones, and β-lactamases. ... 10/27/05 - 20050238637 - Vectors for molecule delivery to cd11b expressing cells The invention relates to a novel use of a Bordetella adenylcyclase toxin in the manufacturing of vectors for targeting in vivo a molecule of interest, specifically to CD11b expressing cells. The invention also relates to an immunogenic composition that primes immune responses, to pharmaceutical compositions, and to a new vector ... 10/27/05 - 20050238636 - Food supplement formulation An improved food supplement formulation comprises fish oil, peppermint oil, and lipase. ... 10/13/05 - 20050226859 - Peg-modified uricase The present invention is directed to uricase modified with polyethylene glycol and to methods of treating different illnesses characterized by increased circulating uric acid levels, including but not limited to, hyperuricemia and tumor lysis syndrome. ... 09/29/05 - 20050214275 - Sequential ordered fatty acid alpha oxidation and delta9 desaturation are major determinants of lipid storage and utilization in adipocytes A method for intentionally modulating by externally directing the amount of fat in a living mammal having adipocyte cells which comprises administering a compound thereto having reactive selectivity to the metabolic regulatory system of the cells of the animal to increase the fatty acid α oxidation of the lipid content ... 09/08/05 - 20050196391 - Method and composition for inhibiting cancer cell growth Improvements in methods of treating cancer with weakly basic anti-cancer compounds are provided. In one aspect, the invention provides an improvement in a method of treating cancer cells whose extracellular environment contains 1-8 mM urea, by exposing the cells to a weakly basic anti-cancer compound which is effective in inhibiting ... 08/04/05 - 20050169906 - Modified human acid spingomyelinase having increased activity, and methods for making the same Deficiencies in the enzymatic activity of acid sphingomyelinase (ASM) result in Niemann-Pick disease. A variety of modifications which eliminate the activity of the free thiol on the C-terminal cysteine residue of ASM all result in substantially increased specific activity of the enzyme. Methods used to alter the activity of this ... 08/04/05 - 20050169905 - Isolated human phosphatase proteins, nucleic acid molecules encoding human phosphatase proteins, and uses thereof The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the phosphatase peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the phosphatase peptides, and methods of identifying ... 07/21/05 - 20050158297 - Masp-2, a complement-fixing enzyme, and uses for it The invention relates to the discovery and characterization of mannan binding lectin-associated serine protease-2 (MASP-2), a new serine protease that acts in the MBLectin complement fixation pathway. ... 06/30/05 - 20050142127 - Isolated human phosphodiesterase proteins, nucleic acid molecules encoding human phosphodiesterase proteins, and uses thereof The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the phosphodiesterase peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the phosphodiesterase peptides, and methods of identifying ... 06/23/05 - 20050136044 - Butyrylcholinesterase variants that alter the activity of chemotherapeutic agents The invention provides a butyrylcholinesterase variant having the amino acid sequence selected from SEQ ID NOS: 4, 6, 8, 10, 12, 14, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, ... 06/09/05 - 20050123530 - Stabilized proteins The invention described herein comprises methods for stabilizing polypeptides and polypeptide complexes, and the polypeptides and polypeptide complexes stabilized using the methods. To achieve stabilization, a cross-link reaction is controlled such that polypeptides and polypeptide complexes maintain their original functionality. In one embodiment, the invention provides a method for the ... 06/09/05 - 20050123529 - Systems and methods related to degradation of uremic toxins The present invention generally relates to the treatment of uremic toxins in vivo using uremic toxin-treating enzymes, and/or cells capable of producing uremic toxin-treating enzymes or otherwise reacting with uremic toxins. Non-limiting examples of cases where the treatment of uremic toxins is desired include renal disease or dysfunction, gout, subjects ... 06/02/05 - 20050118156 - Storage-stable fibrin sealant Provided are supplemented and unsupplemented, ready-to-use and instantly-available fibrin sealants (“FS”), prepared from ready-to-use, storage-stable, concentrated liquid fibrinogen preparations. The thus-produced FS product when applied to a tissue provides the elasticity, tensile strength, and adhesiveness necessary to prevent blood loss, to promote wound healing, and for many other therapeutic and ... ### FreshPatents.com Support |